TABLE 2.
MSCs-mediated treatment of oral cancers.
| MSCs sources | Types of cancer/cell lines | Type of studies | Application methods for MSCs | Outcome effects | References |
|---|---|---|---|---|---|
| Human deciduous exfoliated teeth | CAL27 | In vivo | Multipoint intratumoral injection | Decreased the volume of tumor and the production of microvessels around the tumor | Liu et al. (2022) |
| Human bone marrow | TCA8113 | In vitro and in vivo | Injected subcutaneously | Exosomes transfer miR-101-3p to tumor cells and then inhibited the proliferation, invasion and migration of tumor cells | Xie et al. (2019) |
| Hamster bone marrow | OSCC induced by mineral oil or DMBA | In vivo | Injected around the tumors | MSC administration at papilloma stage precludes tumor growth and epithelial dedifferentiation of OSCC | Bruna et al. (2017) |
| Mice bone marrow | OSCC (moderately differentiated tumor of buccal mucosa) | In vitro | Injected directly intratumorally | Reduced inflammation, increased micro-vascularization, and minimize hypoxia of orthotopic tumor tissues. Combined treatment with Cisplatin leaded to higher apoptotic activity and reduced tumor tissue growth | Zurmukhtashvili et al. (2020) |
| MSCs (species not specified) | OSCC | In vivo | Sonodynamic Treatment, M/LPV/O2 | Induced tumor cells death, displayed good tumor accumulation and penetration under ultrasound stimulation, and efficiently induces tumor inhibition and even abrogation, exhibited minimal systemic adverse effects and successfully maintained oral functions with no facial tissue damage | Sun et al. (2020) |
| Mice bone marrow | Oral potentially malignant disorders | In vivo | BMSCs-EVs-miR-185, directly pasted | Reduced inflammatory conditions and dysplasia of diseased tissue, inhibited proliferation, angiogenesis and promoted activation of the Akt pathway to increase apoptosis | Wang et al. (2019) |
| Human gingival papilla | SCC154 | In vitro | Cell-mediated drug delivery system | GinPa-MSCs effectively binded the drug and released it in an active form and in sufficient quantity to significantly inhibited the growth of tumor | Coccè et al. (2017) |
| Human gingival tissue | TSCC (TCA8113 and CAL27) | In vitro, In vivo | Vehicle for cell-based gene therapy, GMSCs with full-length TRAIL, mixed injection with tumor cells and tail vein injection | Induced massive necrosis and apoptosis of tumor cells in vitro, GMSCFLT reduced or even inhibited the growth of TSCC in vivo | Xia et al. (2015) |
| Human gingival tissue | TSCC (CAL27) | In vitro, In vivo | GMSCs genetically engineered to produce IFN-β as a targeted gene delivery system (GMSCs/IFN-t), injected subcutaneously | Inhibited the proliferation of CAL27 cells in vitro, inhibited the growth of tumor by suppressing cell proliferation and inducing apoptosis in vivo | Du et al. (2019) |
| Human dental Pulp | TSCC (CAL27) | In vitro, In vivo | Modification of Metal-Organic Framework Nanoparticles Using MSCs Membranes to Target tumor (MOF@DPSCM) | Inhibited the growth of OSCC in vitro and in vivo | Zhou et al. (2021) |
The therapeutic effects of MSCs on oral cancers were summed up in Table 2, including MSCs sources, types of cancer/cell lines, types of studies, application methods for MSCs, therapeutic effects, and references.